FOLH1 and neoplasm: The first striking feature of TRT is the wide range of tumour absorbed doses (when absorbed doses are available): i) between 2 and 77 Gy per cycle of 7.4 GBq [177Lu]Lu-DOTA-TATE (n = 41, n = 37, n = 35, n = 90 patients with NETs at different locations) [27–30], ii) between 7.3 and 24.4 Gy from whole body assessment or 3.4–73.9 Gy/GBq in tumour-bearing bone for [177Lu]Lu-DOTA-PSMA (n = 30 patients with mCRPC) [31, 32], iii) between 0.6 and 44.1 Gy for [223Ra]Ra-Cl2 (n = 5 patients with mCRPC) [33] (reviewed in [34]).